Breast Cancer Clinical Case Review

Deborah Toppmeyer, MD, director of the Stacy Goldstein Breast Center and professor of medicine at Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, reveals the chosen therapy for this patient.

Editor’s note: The following is an automatically generated transcript of the above video.

"So what are we prescribing in the first line? Again, if one has a frail patient with cardiac issues, tend to give palbociclib. A young patient, we may give an AI with ovarian suppression, plus ribociclib or abemaciclib. If you look at the activity for real-world data, abemaciclib is particularly effective in the highly endocrine-resistant patient population in those who have been treated. There also seems to be greater CNS penetration with abemaciclib."